NCT06313970View on ClinicalTrials.gov

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 20, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Pancreatic Cancer
Interventions
DRUG

QL1706

QL1706 5mg/kg，IV，D1, Q3W

DRUG

Nab-paclitaxel

Nab-paclitaxel, 125mg/m2，IV，D1、8, Q3W

DRUG

Gemcitabine

gemcitabine，1000mg/m2，IV，D1、8；Q3W.

DRUG

Bevacizumab

bevacizumab, 7.5mg/kg，IV，D1；Q3W.

Trial Locations (1)

Unknown

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER